MSI 136

Drug Profile

MSI 136

Latest Information Update: 04 Dec 1995

Price : $50

At a glance

  • Originator Genaera Corporation
  • Class Amino acids; Antibacterials; Antineoplastics; Peptide antibiotics
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Periodontal disorders

Most Recent Events

  • 04 Dec 1995 Discontinued-Preclinical for Cancer in USA (Unknown route)
  • 21 Nov 1995 New profile
  • 21 Nov 1995 Discontinued-Preclinical for Periodontal disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top